[不可切除胃癌化疗中的争议问题]

[Controversial issues in chemotherapy for inoperable gastric cancer].

作者信息

Koizumi Wasaburo, Tanabe Satoshi, Higuchi Katsuhiko, Sasaki Tohru, Nakayama Norisuke, Nagaba Shizuka, Kitamura Tadashi, Azuma Mizutomo, Saigenji Katsunori

机构信息

Department of Internal Medicine, Kitasato University School of Medicine, Kitasato University, East Hospital, 2-1-1 Asamizodai, Sagamihara, Kanagawa 228-8520, Japan.

出版信息

Gan To Kagaku Ryoho. 2003 Sep;30(9):1249-55.

PMID:14518402

Abstract

Randomized trials demonstrated the significantly improved survival benefit of 5-fluorouracil (5-FU) based chemotherapy in patients with unresectable advanced gastric cancer (AGC) in comparison with best supportive care (BSC). However there is no chemotherapy considered worldwide to be the standard treatment for AGC and there is no consensus as to whether combination or single agent therapy is preferable. Therefore, 2 large Phase III studies JCOG 9912 5-FU vs TS-1 vs CPT + CDDP and TS-1 vs TS-1 + CDDP are now ongoing to establish an acceptable frontline standard for patients with AGC. We need to develop new agents and combination chemotherapy regimens to achieve greater survival benefit in AGC.

摘要

随机试验表明，与最佳支持治疗（BSC）相比，以5-氟尿嘧啶（5-FU）为基础的化疗在不可切除的晚期胃癌（AGC）患者中显著提高了生存获益。然而，全世界尚无化疗被认为是AGC的标准治疗方法，对于联合治疗还是单药治疗更可取也没有共识。因此，两项大型III期研究JCOG 9912（5-FU对比TS-1对比CPT + CDDP）和TS-1对比TS-1 + CDDP正在进行，以确立AGC患者可接受的一线标准。我们需要开发新的药物和联合化疗方案，以在AGC中获得更大的生存获益。